Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Persistent Pulmonary Hypertension in Neonates With Nebulized Magnesium Sulfate

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newborns with documented persistent pulmonary hypertension as confirmed by echocardiography.~* Neonates born at ≥ 35 wk. gestation with a birth weight of 2.5-4 kg~* Neonates have to be connected to mechanical ventilation with an oxygenation index (OI) \>30 on two occasions at least 15 min apart.~* The echocardiogram had to show a predominant right-to-left or bidirectional shunt (through ductus arteriosus and/or foramen oval) and/or tricuspid regurgitant jet with a pressure gradient ≥ 2/3 of the systemic systolic blood pressure.~Exclusion Criteria:~* Infants of parents who refuse to give informed consent.~* Infants of mothers who receive magnesium sulfate within 48 h before labor.~* Congenital heart diseases other than patent ductus arteriosus (PDA) and foramen ovale.~* Major congenital anomalies, including congenital diaphragmatic hernia and lung hypoplasia.~* Prior need for cardiopulmonary resuscitation~* Mean arterial blood pressure (MABP) \< 35 mmHg despite therapy with volume infusions and vasoactive inotropes.~* Impaired kidney function; and prior administration of pulmonary vasodilators or prior administration of surfactant.

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 3 Days
- Healthy Volunteers: f

Study Arms:
- Nebulized magnesium (NebMag) group 1 (Type: ACTIVE_COMPARATOR): NebMag group (n=20) was administered nebulized isotonic magnesium (64 mg/mL). For nebulization, an isotonic MgSO₄ solution (64 mg/mL) was formulated by diluting a 10% intravenous preparation of MgSO₄ heptahydrate with sterile distilled water. 4 mL aliquots of the isotonic MgSO₄ solution (containing 256 mg of MgSO₄) were administered every 15 minutes through the jet nebulizer connected to the ventilator during the 24 hour study period.
- Intravenous magnesium (IVMag) group 2 (Type: ACTIVE_COMPARATOR): IVMag group (n=20) received intravenous magnesium. For intravenous administration, a 10% MgSO₄ solution was prepared by diluting a 50% intravenous formulation of MgSO₄ heptahydrate with 5% glucose and administrated in a loading dose of 2 mL/kg over 30 minutes (equivalent to 200 mg/kg of MgSO₄), followed by a continuous infusion at a rate of 0.5 mL/kg/h (equivalent to 50 mg/kg/h of MgSO₄) over the 24 hour study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).